This is how Bernstein divvies up a $40B Covid-19 vaccine market among the leaders in the race to an approval
The frenzied race to regulatory approvals this year is coming down to the finish line. The winners can immediately pivot to the competition for the mega-blockbuster revenue gains to come as the starting gun is fired for the global race to seize market share.
Pfizer $PFE and their development partners at BioNTech have seized a clear — though small — lead in the race to win FDA approval for the first Covid-19 vaccine. And the analyst team working with Bernstein’s Ronny Gal says the pharma giant also has the muscle to seize a clear advantage in winning the biggest slice of the $40 billion market that lies in wait for the leading players next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.